As the U.S. locks up supplies to make Pfizer's COVID-19 vaccine, Serum Institute of India and WHO are raising flags about global supply bottlenecks and raw materials shortfalls, Bloomberg reports. The supply disruption comes after the Biden administration tapped the Defense Production Act to increase deliveries of Pfizer's shot in the U.S.
Takeda s latest sale brings its total divestment value up to about $12.9 billion. (Takeda)
After inking a slate of geography-specific product selloffs last year, Takeda has turned back to Japan.
Takeda locked up a deal to sell four Type 2 diabetes meds in Japan to local drugmaker Teijin Pharma for 133 billion Japanese yen ($1.2 billion), freeing up the company to focus on its core businesses in gastroenterology, rare diseases, plasma-derived therapies, oncology and neuroscience.
The move is the latest in Takeda s selloff spree, linked to a divesture goal it set alongside its Shire merger. The company has already exceeded its $10 billion target, but has shown no sign of slowing down, as it continued to shave off noncore products late into 2020 and early 2021.
Mar 4, 2021 10:54am
The FDA has expanded Pfizer s Lorbrena approval to include front-line ALK-positive non-small cell lung cancer.
Pfizer’s Lorbrena has finally broken into front-line non-small cell lung cancer, where Novartis, Roche and Takeda are already jockeying for a niche market.
The FDA expanded Lorbrena’s use into newly diagnosed patients with ALK-positive NSCLC, Pfizer said Wednesday. With that front-line nod, the agency converted Lorbrena s conditional green light for previously treated cases into a full approval.
How does Pfizer expect to compete in such a crowded field? As a third-generation ALK inhibitor, Lorbrena has arguably the best efficacy data in head-to-head tests against its predecessor, Xalkori.
Mar 4, 2021 11:33am
Roche decided in 2015 to close four small-molecule manufacturing plants around the world. It found buyers for three. But the one that the company couldn t sell was in Clarecastle, Ireland. Destruction of the facility begins in June. (Roche)
Unable to sell its plant in Clarecastle, Ireland, Roche will take a wrecking ball to the facility in June.
It won’t be a simple process. In fact, a timeline of June 2021 to May 2028 has been listed for the project, which requires removing 10 buildings and infrastructure from the 88-acre site.
The most painstaking aspect of the operation will be recovery and removal of what lies underneath: Nearly 40,000 metric tons of waste has been identified on the property. And the project will require more than 90,000 metric tons of backfill to patch up the land afterward.
CureVac, Novartis team up in latest pandemic vaccine manufacturing collaboration fiercepharma.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from fiercepharma.com Daily Mail and Mail on Sunday newspapers.